🇺🇸

US SEC Filing Intelligence

· daily

Significant Contract Modifications ($10M+) — July 26, 2026

Over the single-day period of July 26, 2026, two civilian agency contracts totaling $293.96 million were awarded, with zero defense-related obligations. The dominant theme is federal support for border-related infrastructure and workforce training, led by a $156.8M Department of Interior award to DEPLOYED SERVICES, LLC for facilities support at a Texas Influx Care Facility, and a $137.1M Department of Labor award to MANAGEMENT & TRAINING CORPORATION for Job Corps operations. The highest-conviction signal is the massive $2.8B potential upside in the DEPLOYED SERVICES contract if all options are exercised, though the two-year base period and time-and-materials pricing introduce execution and revenue visibility risks. Investors should watch for option exercises at the Carrizo Springs facility and the January 2024 re-compete for the MTC Job Corps contract as key catalysts.

2 total filings
· daily

Contract Deobligations Alert — July 26, 2026

This digest covers two civilian agency contracts totaling $293.96 million, with zero defense-related awards, signaling a muted week for defense-exposed portfolios. The dominant theme is civilian operational support, led by a $156.8M Department of the Interior award to DEPLOYED SERVICES, LLC for border-related facilities support, which carries a massive $2.8B potential upside if all options are exercised—a high-conviction catalyst. The second award, a $137.1M Department of Labor contract to MANAGEMENT & TRAINING CORPORATION for Job Corps operations, is a low-risk, stable revenue stream but faces political sensitivity around job training funding. Key risk: the DEPLOYED SERVICES contract is time-and-materials, introducing cost overrun exposure, and its two-year base period limits long-term visibility. Investors should watch for option exercises and follow-on awards to validate revenue diversification.

2 total filings
· daily

Contract Option Exercises — July 26, 2026

The two civilian agency contracts totaling $293.96 million signal stable but low-growth spending in non-defense operational support, with zero defense exposure. The Department of the Interior's $156.8M award to DEPLOYED SERVICES, LLC for border facility support is the highest-conviction signal, offering a potential $2.8B upside if all options are exercised, but carries medium risk due to time-and-materials pricing and geographic concentration at a single site. The Department of Labor's $137.1M cost-plus contract to Management & Training Corporation for Job Corps operations provides low-risk, capped margins but faces political budget risk. Key watch item: the MTC contract expires January 2024, creating a re-compete catalyst that could disrupt or confirm MTC's incumbent position.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — July 26, 2026

This digest covers two civilian agency contracts totaling $293.96 million, with zero defense-related awards, underscoring a non-defense procurement focus. The dominant theme is federal support services for social infrastructure: a $156.8M Department of the Interior facilities support award to DEPLOYED SERVICES, LLC at a border influx care facility, and a $137.1M Department of Labor job training center contract to MANAGEMENT & TRAINING CORPORATION. The highest-conviction signal is the substantial potential upside for DEPLOYED SERVICES, LLC if all options are exercised, bringing the total value to $2.8B. Key risks include the time-and-materials pricing structure for the Interior contract and the upcoming expiration of the Labor contract in January 2024, which introduces renewal uncertainty.

2 total filings
· daily

High-Value Federal Grants ($5M+) — July 26, 2026

The two civilian contracts, totaling $293.96 million, show no defense exposure, underscoring a pure civilian-services theme. The dominant signal is a $156.85M Department of the Interior award to DEPLOYED SERVICES, LLC for border-related facilities support, carrying a massive $2.8B options upside but concentrated in a single location and time-and-materials pricing risk. A second $137.1M Department of Labor award to Management & Training Corporation for Job Corps operations is lower-risk but offers capped margins. The highest-conviction signal is the potential for DEPLOYED SERVICES to scale dramatically if options are exercised, though the lack of defense contracts and neutral signals across both awards limit near-term bullish catalysts. Key risk is the concentration of DEPLOYED SERVICES' revenue at one facility and the upcoming January 2024 contract end for MTC.

2 total filings
· daily

General Federal Contracts — July 26, 2026

This digest covers two civilian agency contracts totaling $293.96 million with zero defense-related awards, signaling stable but non-growth-oriented federal spending in operational support and social services. The dominant theme is Department of the Interior border infrastructure spending, led by a $156.8M award to DEPLOYED SERVICES, LLC for facilities support at an Influx Care Facility in Carrizo Springs, TX, which carries a massive $2.8B potential upside if all options are exercised. A second $137.1M cost-plus contract to MANAGEMENT & TRAINING CORPORATION for Job Corps operations highlights low-risk, capped-margin revenue streams in politically sensitive civilian programs. The highest-conviction signal is the DEPLOYED SERVICES award's option structure, which could drive multi-year revenue growth but introduces execution and geographic concentration risk. Key watch items include option exercise decisions for the Carrizo Springs facility and the January 2024 contract end date for MTC's Job Corps program.

2 total filings
· daily

New Federal Contractors — July 25, 2026

This digest covers a single $101.3M civilian contract awarded to General Dynamics Information Technology (GDIT) by the Department of Health and Human Services (CMS) for software asset management support. The contract, won under full and open competition, signals GDIT's competitive strength in the health IT services sector and provides moderate revenue visibility through 2027. The highest-conviction signal is the competitive win against other large IT contractors, though the fixed-price structure introduces execution risk. Key watch items include margin performance and option exercise announcements, with no defense exposure in this period.

1 total filings
· daily

Contract Deobligations Alert — July 25, 2026

The sole contract in this digest is a $101.3 million civilian award to General Dynamics Information Technology (GDIT) from the Department of Health and Human Services (CMS) for software asset management support, with options that could raise the total to $147.5 million. This is a moderate bullish signal for General Dynamics Corp (GD), demonstrating competitive strength in the health IT services market via a full-and-open competition win. The contract provides two years of recurring revenue visibility, though the fixed-price structure introduces execution risk on margins. With zero defense-related awards in this period, the digest highlights a civilian IT services opportunity rather than a defense-driven catalyst. Key watch items include GDIT's margin performance and the exercise of options in 2027.

1 total filings
· daily

Contract Option Exercises — July 25, 2026

This digest covers a single contract option exercise period totaling $101.3 million, entirely civilian (0% defense), awarded to General Dynamics Information Technology (GDIT) by the Department of Health and Human Services (HHS/CMS) for software asset management support. The award is a firm-fixed-price delivery order under full and open competition, signaling GDIT's competitive strength in the health IT services niche. The contract provides recurring revenue visibility through July 2027 with a potential extension to 2028, but the fixed-price structure introduces medium execution risk. The key watch item is GDIT's margin performance on this contract, given the fixed-price nature and the broader CMS IT budget trajectory.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — July 25, 2026

The digest covers a single $101.3M civilian IT contract awarded to General Dynamics Information Technology (GDIT) by the Department of Health and Human Services (HHS/CMS) for software asset management support. This is a pure civilian win with no defense exposure, reflecting stable demand for health IT services. The highest-conviction signal is a moderate bullish indicator for General Dynamics Corp, as the competitive full-and-open award demonstrates GDIT's strength in the health IT market. Key risks include the fixed-price contract structure, which may pressure margins, and the absence of defense-related contracts in this period, limiting sector diversification.

1 total filings
· daily

All HHS Contracts — July 25, 2026

This digest covers a single high-value civilian health contract worth $101.3 million awarded to General Dynamics Information Technology (GDIT) by the Centers for Medicare & Medicaid Services (CMS), with total obligations reaching $101.3M. The contract is entirely civilian (0% defense) and reflects sustained federal IT spending in healthcare administration, specifically for software asset management. The highest-conviction signal is a moderate bullish indicator for General Dynamics Corp (GD), as GDIT won a competitive, full-and-open contract against other large IT players, though the fixed-price structure introduces medium execution risk. A key watch item is GDIT's margin performance on this fixed-price engagement and the potential for option exercises that could lift total value to $147.5M by 2028.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — July 25, 2026

This single-contract digest covers a $101.3 million civilian award to General Dynamics Information Technology (GDIT) from the Department of Health and Human Services (HHS/CMS), with zero defense-related activity. The contract is a firm-fixed-price delivery order for software asset management support, won under full and open competition, signaling GDIT’s competitive strength in the health IT services niche. The highest-conviction signal is the moderate bullish revenue visibility for General Dynamics Corp (GD), though the fixed-price structure introduces execution risk on margins. Key watch items include option exercise announcements in 2027 and CMS IT budget trends, as the contract’s value could expand to $147.5 million with options.

1 total filings
· daily

High-Value Federal Grants ($5M+) — July 25, 2026

The single high-value federal grant recorded on July 25, 2026, totals $101.3M (with options up to $147.5M) and is entirely civilian, awarded by HHS/CMS to General Dynamics Information Technology for software asset management support. This competitive, full-and-open award underscores sustained civilian health IT spending, though the fixed-price structure introduces margin execution risk. The single-record digest offers a modestly bullish signal for General Dynamics Corp (GD), but with low overall materiality relative to GD's $60B+ revenue base. Key monitoring points include option exercise timing (2027) and CMS IT budget continuity under a potential Continuing Resolution.

1 total filings
· daily

General Federal Contracts — July 25, 2026

This digest covers a single civilian contract totaling $101.3M, awarded by the Department of Health and Human Services (CMS) to General Dynamics Information Technology (GDIT) for software asset management support. The contract is a firm-fixed-price delivery order with options that could bring the total value to $147.5M, providing moderate revenue visibility through 2027-2028. The highest-conviction signal is a bullish competitive win for GDIT in a full-and-open competition, demonstrating its strength in the health IT services market. However, the fixed-price structure introduces medium execution risk, and the contract's materiality to General Dynamics Corp is moderate, given the company's $60B+ revenue base. Key watch items include GDIT's margin performance on this contract and potential option exercises in 2027.

1 total filings
· daily

Biotech Small-Cap Approvals — July 24, 2026

This digest covers 10 FDA approvals from July 17-24, 2026, all classified as 'Other' (non-NME, non-biosimilar, non-label-expansion under standard definitions, though the data stream labels some as biosimilar and label expansion). The mix includes 0 NMEs, 0 true biosimilars (per standard definition), and 0 label expansions by the digest's count, but individual entries show 8 biosimilar-like approvals and 2 label expansions. The dominant theme is generic/biosimilar competition across diverse therapeutic areas, with no single sector cluster. The highest-conviction bullish signals are the label expansions for SIROLIMUS (AFT PHARMACEUTICALS LTD) and EDARAVONE (AZURITY PHARMACEUTICALS INC), which may open new patient populations or indications. A key watch item is the lack of NME approvals, signaling a quiet period for novel drug catalysts, and the neutral-to-bullish bias (2 bullish, 0 bearish) suggests limited downside risk but also limited upside for high-growth biotech investors.

10 total filings
· daily

Orphan Drug Approvals — July 24, 2026

The July 24, 2026 orphan drug approval stream contained a single label expansion for SIROLIMUS (SCOMARA) by AFT PHARMACEUTICALS LTD, classified as a fallback approval with a moderately bullish signal. There were no NMEs or biosimilars approved, limiting the period's investment impact to a narrow, sponsor-specific event. The highest-conviction signal is the label expansion for SIROLIMUS, which may broaden its commercial use in a rare disease setting, though peak sales and exclusivity details remain undisclosed. Key risks include the absence of pricing power data and the lack of clarity on market positioning, which tempers the bullish thesis for AFT PHARMACEUTICALS LTD.

1 total filings
· daily

New Drug Approvals (Original) — July 24, 2026

The July 24, 2026 FDA approval digest is dominated by 10 generic/biosimilar approvals, with zero NMEs, biosimilars, or label expansions formally classified, though two approvals (SIROLIMUS and EDARAVONE) carry bullish label expansion signals. The period is characterized by high-volume generic entries from sponsors like AUROBINDO PHARMA LTD, TEVA PHARMS USA, and ZYDUS PHARMS, indicating a wave of off-patent competition across dermatology, CNS, and metabolic therapeutic areas. The highest-conviction signal is the label expansion for EDARAVONE by AZURITY PHARMACEUTICALS INC, which may broaden its addressable market in neurology, though commercial details remain undisclosed. Key risk is the lack of NME approvals, signaling a dry pipeline for novel therapies and potential investor rotation toward later-stage generic players.

10 total filings
· daily

Federal Construction & Infrastructure Contracts — July 24, 2026

This digest covers a single $130.8M civilian contract awarded to PTSI MANAGED SERVICES INC by NASA for facility design and construction at Goddard Space Flight Center, with zero defense-related exposure. The contract is substantially complete (78% paid) and was awarded under full-and-open competition on a firm-fixed-price basis, signaling stable but non-exclusive positioning in NASA infrastructure. The highest-conviction signal is neutral: the contract demonstrates successful execution over a six-year period, but the lack of follow-on awards or set-aside protections raises concentration risk for PTSI. Key watch items include PTSI's ability to win new NASA GSFC contracts post-2023 and the absence of any defense diversification in this stream.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — July 24, 2026

This digest covers a single, high-value civilian contract awarded to Leidos Holdings, Inc. via its subsidiary Leidos Biomedical Research Inc. The Department of Health and Human Services (HHS), specifically the NIH National Cancer Institute, obligated $173.3 million for Phase 1 and Phase 2 vaccine clinical trials. The contract is a cost-plus-fixed-fee delivery order with a six-year performance period (through May 2029) and $36.8 million already funded, providing Leidos with stable, low-risk revenue visibility. The highest-conviction signal is the low pricing risk and long duration, though the full $173.3 million realization depends on future funding obligations. There are no defense-related contracts in this period.

1 total filings